keyword
Keywords "no evidence of disease activi...

"no evidence of disease activity" AND "multiple sclerosis"

https://read.qxmd.com/read/38532143/early-prediction-of-unfavorable-evolution-after-a-first-clinical-episode-suggestive-of-multiple-sclerosis-the-eumus-score
#1
JOURNAL ARTICLE
Giulia Mallucci, Ottavia Eleonora Ferraro, Maria Trojano, Maria Pia Amato, Antonio Scalfari, Mauro Zaffaroni, Elena Colombo, Eleonora Rigoni, Pietro Iaffaldano, Emilio Portaccio, Lorenzo Saraceno, Damiano Paolicelli, Lorenzo Razzolini, Cristina Montomoli, Roberto Bergamaschi
BACKGROUND: Predicting disease progression in patients with the first clinical episode suggestive of multiple sclerosis (MS) is crucial for personalized therapeutic approaches. This study aimed to develop the EUMUS score for accurately estimating the risk of early evidence of disease activity and progression (EDA). METHODS: Retrospective analysis was conducted on data from 221 patients with a first clinical MS episode collected from four Italian MS centers. Various variables including socio-demographics, clinical features, cerebrospinal fluid analysis, evoked potentials, and brain MRI were considered...
March 26, 2024: Journal of Neurology
https://read.qxmd.com/read/38513425/substantial-and-comparable-suppression-of-disease-activity-following-early-initiation-of-cladribine-tablets-ocrelizumab-or-alemtuzumab-as-first-pharmacologic-treatment-for-relapsing-multiple-sclerosis-a-real-world-study
#2
JOURNAL ARTICLE
Raed Alroughani, Jasem Al-Hashel, Samar Farouk Ahmed
BACKGROUND: We describe the efficacy and safety of recent high efficacy disease DMTs in DMT-naive patients with highly active RMS. METHODS: This was a retrospective, cross sectional study from the Kuwait national MS registry. Patients with RMS who received alemtuzumab, cladribine tablets or ocrelizumab as their first DMT for RMS, with ≥2 year of follow up were included. The primary endpoint was the change in relapse rate from treatment initiation to 1 year; changes in disability (Expanded Disability Status Scale [EDSS]), radiologic activity, the proportion with no evidence of disease activity-3 (NEDA-3), and the frequency of adverse events were secondary endpoints...
March 19, 2024: Clinical Neurology and Neurosurgery
https://read.qxmd.com/read/38418770/real-world-retrospective-analysis-of-alemtuzumab-outcomes-in-relapsing-remitting-multiple-sclerosis-the-lemcam-study
#3
JOURNAL ARTICLE
Lucienne Costa-Frossard França, Virginia Meca Lallana, Andrés Labiano-Fontcuberta, Rosario Blasco, Enric Monreal, María Luisa Martínez Ginés, Clara Aguirre, Julia Sabin Muñoz, Susana Sainz de la Maza, Juan Pablo Cuello, Carolina Díaz-Pérez, Juan Luis Chico García, Alberto Lozano Ros, Fernando Rodríguez Jorge, Susana Martínez Martínez, José Manuel García Domínguez
BACKGROUND: Alemtuzumab is a high-efficacy treatment approved for relapsing-remitting multiple sclerosis (RRMS). Although clinical trials and observational studies are consistent in showing its efficacy and manageable safety profile, further studies under clinical practice conditions are needed to further support its clinical use. OBJECTIVE: The aim of this observational retrospective study was to evaluate the effectiveness and safety of alemtuzumab to add to the current real-world evidence on the drug...
February 28, 2024: CNS Drugs
https://read.qxmd.com/read/38375947/rituximab-treatment-in-pediatric-onset-multiple-sclerosis
#4
JOURNAL ARTICLE
Markus Breu, Fredrik Sandesjö, Ruxandra-Iulia Milos, Jan Svoboda, Jonatan Salzer, Lisa Schneider, Julian Benedikt Reichelt, Annikki Bertolini, Astrid Blaschek, Katharina Fink, Romana Höftberger, Jan Lycke, Kevin Rostásy, Rainer Seidl, Sandy Siegert, Ronny Wickström, Barbara Kornek
BACKGROUND AND PURPOSE: Rituximab (RTX) is frequently used off-label in multiple sclerosis. However, studies on the risk-benefit profile of RTX in pediatric-onset multiple sclerosis are scarce. METHODS: In this multicenter retrospective cohort study, patients with pediatric-onset multiple sclerosis from Sweden, Austria and Germany, who received RTX treatment were identified by chart review. Annualized relapse rates, Expanded Disability Status Scale scores and magnetic resonance imaging parameters (new T2 lesions and contrast-enhancing lesions) were assessed before and during RTX treatment...
February 20, 2024: European Journal of Neurology
https://read.qxmd.com/read/38345003/autologous-hematopoietic-stem-cell-transplantation-for-multiple-sclerosis-long-term-follow-up-data-from-norway
#5
JOURNAL ARTICLE
Christopher Elnan Kvistad, Anne Kristine Lehmann, Silje Agnethe Stokke Kvistad, Trygve Holmøy, Åslaug Rudjord Lorentzen, Linn Hereide Trovik, Einar Klæboe Kristoffersen, Lars Bø, Øivind Torkildsen
BACKGROUND: Autologous hematopoietic stem cell transplantation (HSCT) is a potent treatment option for patients with aggressive relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To evaluate long-term outcomes of HSCT in MS. METHODS: National retrospective single-center observational study of patients with aggressive RRMS that underwent HSCT in Norway from January 2015 to January 2018. Criteria for receiving HSCT included at least two clinical relapses the last year while on disease modifying treatment (DMT)...
February 12, 2024: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/38224478/efficacy-and-safety-of-the-natural-killer-t-cell-stimulatory-glycolipid-och-ncnp1-for-patients-with-relapsing-multiple-sclerosis-protocol-for-a-randomized-placebo-controlled-clinical-trial
#6
JOURNAL ARTICLE
Tomoko Okamoto, Takami Ishizuka, Reiko Shimizu, Yasuko Asahina, Harumasa Nakamura, Yuko Shimizu, Yoichiro Nishida, Takanori Yokota, Youwei Lin, Wakiro Sato, Takashi Yamamura
BACKGROUND: Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system that causes myelin sheath damage and axonal degeneration. The glycolipid (2S, 3S, 4R)-1-O-(α-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonaetriol (OCH-NCNP1 or OCH) exerts an immunoregulatory action that suppresses T helper (Th)1 cell-mediated immune responses through natural killer T cell activation, selective interleukin-4 production, and Th2 bias induction in human CD4-positive natural killer T cells...
January 15, 2024: JMIR Research Protocols
https://read.qxmd.com/read/38176284/benefits-of-ahsct-over-alemtuzumab-in-patients-with-multiple-sclerosis-besides-disability-and-relapses-sustained-improvement-in-cognition-and-quality-of-life
#7
JOURNAL ARTICLE
Bente Braun, Felix Fischbach, Johanna Richter, Lena Kristina Pfeffer, Heike Fay, Stefanie Reinhardt, Manuel A Friese, Jan-P Stellmann, Nicolaus M Kröger, Christoph Heesen, Vivien Häußler
BACKGROUND: Autologous hematopoietic stem cell transplantation (aHSCT) exhibits promising results for multiple sclerosis (MS) in the short term. We investigated the long-term outcome differences in disease progression and cognitive impairment after aHSCT and alemtuzumab treatment. METHODS: 20 patients receiving aHSCT and 21 patients treated with alemtuzumab between 2007 and 2020 were included in this monocentric observational cohort study. The primary objective was to compare the outcome of both groups with regards to achieving No Evidence of Disease Activity (NEDA-3), defined by the absence of relapses, EDSS progression, and MRI activity...
December 27, 2023: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38133801/predicting-disease-severity-in-multiple-sclerosis-using-multimodal-data-and-machine-learning
#8
JOURNAL ARTICLE
Magi Andorra, Ana Freire, Irati Zubizarreta, Nicole Kerlero de Rosbo, Steffan D Bos, Melanie Rinas, Einar A Høgestøl, Sigrid A de Rodez Benavent, Tone Berge, Synne Brune-Ingebretse, Federico Ivaldi, Maria Cellerino, Matteo Pardini, Gemma Vila, Irene Pulido-Valdeolivas, Elena H Martinez-Lapiscina, Sara Llufriu, Albert Saiz, Yolanda Blanco, Eloy Martinez-Heras, Elisabeth Solana, Priscilla Bäcker-Koduah, Janina Behrens, Joseph Kuchling, Susanna Asseyer, Michael Scheel, Claudia Chien, Hanna Zimmermann, Seyedamirhosein Motamedi, Josef Kauer-Bonin, Alex Brandt, Julio Saez-Rodriguez, Leonidas G Alexopoulos, Friedemann Paul, Hanne F Harbo, Hengameh Shams, Jorge Oksenberg, Antonio Uccelli, Ricardo Baeza-Yates, Pablo Villoslada
BACKGROUND: Multiple sclerosis patients would benefit from machine learning algorithms that integrates clinical, imaging and multimodal biomarkers to define the risk of disease activity. METHODS: We have analysed a prospective multi-centric cohort of 322 MS patients and 98 healthy controls from four MS centres, collecting disability scales at baseline and 2 years later. Imaging data included brain MRI and optical coherence tomography, and omics included genotyping, cytomics and phosphoproteomic data from peripheral blood mononuclear cells...
December 22, 2023: Journal of Neurology
https://read.qxmd.com/read/38130338/dairy-and-gluten-in-disease-activity-in-multiple-sclerosis
#9
JOURNAL ARTICLE
Isabel A Temperley, Alexandra N Seldon, Madeline Aw Reckord, Claudia A Yarad, Farihah T Islam, Kerith Duncanson, Rodney A Lea, Jeannette Lechner-Scott, Vicki E Maltby
BACKGROUND: Many diets promoted specifically for multiple sclerosis have been suggested to improve disease activity. Dairy and gluten are two components for which the recommendations vary between these diets. Existing research into the association between these dietary components and disease activity has been conflicting. OBJECTIVE: To explore the relationship between dairy and gluten intake and disease activity in multiple sclerosis over a 2-year period, using no evidence of disease activity (NEDA) 3 status...
2023: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://read.qxmd.com/read/38034162/stem-cell-transplantation-for-multiple-sclerosis-a-2023-review-of-published-studies
#10
REVIEW
Ali Msheik, Farah Assi, Faten Hamed, Ali Jibbawi, Anna-Marina Nakhl, Anthony Khoury, Rami Mohanna, Teddy Gerges, Rami Atat
This comprehensive literature review underscores the potential of stem cell transplantation (SCT) as a therapeutic intervention for multiple sclerosis (MS). By amalgamating evidence from various sources, including randomized controlled trials (RCTs), observational, retrospective, and comparative studies, this review offers a holistic understanding of SCT's effectiveness, safety, and feasibility in diverse contexts of MS management. SCT has shown promise in mitigating disease activity and progression, particularly in relapsing-remitting MS (RRMS)...
October 2023: Curēus
https://read.qxmd.com/read/37893133/micrornas-associated-with-disability-progression-and-clinical-activity-in-multiple-sclerosis-patients-treated-with-glatiramer-acetate
#11
JOURNAL ARTICLE
Ignacio Casanova, María I Domínguez-Mozo, Laura De Torres, Yolanda Aladro-Benito, Ángel García-Martínez, Patricia Gómez, Sara Abellán, Esther De Antonio, Roberto Álvarez-Lafuente
MicroRNAs (miRNAs) are promising biomarkers in multiple sclerosis (MS). This study aims to investigate the association between a preselected list of miRNAs in serum with therapeutic response to Glatiramer Acetate (GA) and with the clinical evolution of a cohort of relapsing-remitting MS (RRMS) patients. We conducted a longitudinal study for 5 years, with cut-off points at 2 and 5 years, including 26 RRMS patients treated with GA for at least 6 months. A total of 6 miRNAs from a previous study (miR-9.5p, miR-126...
October 12, 2023: Biomedicines
https://read.qxmd.com/read/37882961/assessing-sustained-b-cell-depletion-and-disease-activity-in-a-french-multiple-sclerosis-cohort-treated-by-long-term-iv-anti-cd20-antibody-therapy
#12
JOURNAL ARTICLE
Sean A Freeman, Bruno Lemarchant, Tifanie Alberto, Julie Boucher, Olivier Outteryck, Myriam Labalette, Stéphanie Rogeau, Sylvain Dubucquoi, Hélène Zéphir
Few studies have investigated sustained B-cell depletion after long-term intravenous (IV) anti-CD20 B-cell depleting therapy (BCDT) in multiple sclerosis (MS) with respect to strict and/or minimal disease activity. The main objective of this study was to investigate how sustained B-cell depletion after BCDT influences clinical and radiological stability as defined by "no evidence of disease activity" (NEDA-3) and "minimal evidence of disease activity" (MEDA) status in MS patients at 12 and 18 months. Furthermore, we assessed the frequency of serious adverse events (SAE), and the influence of prior lymphocytopenia-inducing treatment (LIT) on lymphocyte subset counts and gammaglobulins in MS patients receiving long-term BCDT...
October 26, 2023: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/37861931/effectiveness-and-safety-of-teriflunomide-in-relapsing-remitting-multiple-sclerosis-and-improvements-in-quality-of-life-results-from-the-real-world-tericare-study
#13
JOURNAL ARTICLE
José E Meca-Lallana, José M Prieto González, Ana B Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A García-Estévez, Ana M López Real, Miguel A Llaneza González, María E Marzo Sola, José L Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
INTRODUCTION: Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing-remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinical trials and a real-world setting on efficacy, tolerability and patient-reported benefits. The TERICARE study assessed the impact of teriflunomide treatment over 2 years on health-related quality of life (HRQoL) and some of the most common and disabling symptoms of MS, such as fatigue and depression...
October 20, 2023: Neurology and Therapy
https://read.qxmd.com/read/37857813/a-real-world-clinical-validation-for-ai-based-mri-monitoring-in-multiple-sclerosis
#14
JOURNAL ARTICLE
Michael Barnett, Dongang Wang, Heidi Beadnall, Antje Bischof, David Brunacci, Helmut Butzkueven, J William L Brown, Mariano Cabezas, Tilak Das, Tej Dugal, Daniel Guilfoyle, Alexander Klistorner, Stephen Krieger, Kain Kyle, Linda Ly, Lynette Masters, Andy Shieh, Zihao Tang, Anneke van der Walt, Kayla Ward, Heinz Wiendl, Geng Zhan, Robert Zivadinov, Yael Barnett, Chenyu Wang
Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical relapses, no magnetic resonance imaging (MRI) disease activity and no disability worsening. While MRI is the principal tool available to neurologists for monitoring clinically silent MS disease activity and, where appropriate, escalating treatment, standard radiology reports are qualitative and may be insensitive to the development of new or enlarging lesions. Existing quantitative neuroimaging tools lack adequate clinical validation...
October 19, 2023: NPJ Digital Medicine
https://read.qxmd.com/read/37834042/genetic-variant-hla-drb1-0403-and-therapeutic-response-to-disease-modifying-therapies-in-multiple-sclerosis-a-case-control-study
#15
JOURNAL ARTICLE
Esteban Alejandro Gomez-Gaitan, Yessica Eleanet Garcia-Ortega, Ana Miriam Saldaña-Cruz, Betsabe Contreras-Haro, Jorge Ivan Gamez-Nava, Emilio Edsaul Perez-Guerrero, Cesar Arturo Nava-Valdivia, Sergio Gallardo-Moya, Alejandra Martinez-Hernandez, Laura Gonzalez Lopez, Blanca Esthela Rios-Gonzalez, Jazmin Marquez-Pedroza, Miriam Mendez-Del Villar, Yussef Esparza-Guerrero, Alejandra Villagomez-Vega, Miguel Angel Macias Islas
Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis...
September 27, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37819598/no-evidence-of-disease-activity-neda-as-a-clinical-assessment-tool-for-multiple-sclerosis-clinician-and-patient-perspectives-narrative-review
#16
REVIEW
Scott D Newsome, Cherie Binns, Ulrike W Kaunzner, Seth Morgan, June Halper
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no evidence of disease activity (NEDA). The most common NEDA definition, termed NEDA-3, is a composite of three related measures of disease activity: no clinical relapses, no disability progression, and no radiological activity. NEDA has been frequently used as a composite endpoint in clinical trials, but there is growing interest in its use as an assessment tool to help patients and healthcare professionals navigate treatment decisions in the clinic...
October 11, 2023: Neurology and Therapy
https://read.qxmd.com/read/37808497/a-five-year-observational-prospective-mono-center-study-of-the-efficacy-of-alemtuzumab-in-a-real-world-cohort-of-patients-with-multiple-sclerosis
#17
JOURNAL ARTICLE
Sofia Sandgren, Lenka Novakova, Anna Nordin, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
BACKGROUND: Alemtuzumab (ALZ) is a pulsed immune reconstitution therapy for multiple sclerosis (MS). OBJECTIVE: To assess basic characteristics, therapeutic effects, and prognostic biomarkers on clinical and imaging parameters of disease activity for relapsing-remitting MS (RRMS) patients selected for ALZ, in a real-world long-term setting. METHODS: Fifty-one RRMS patients [female = 31; mean age 36 (standard deviation 7.1) years; median expanded disability status scale (EDSS) 2 (interquartile range (IQR) 1...
2023: Frontiers in Neurology
https://read.qxmd.com/read/37781240/clinical-predictors-of-neda-3-one-year-after-diagnosis-of-pediatric-multiple-sclerosis-an-exploratory-single-center-study
#18
JOURNAL ARTICLE
Filipe Palavra, Diogo Silva, Catarina Fernandes, Ricardo Faustino, Mónica Vasconcelos, Cristina Pereira, Carmen Costa, Joana Afonso Ribeiro, Joana Amaral, Conceição Robalo
INTRODUCTION: Multiple sclerosis (MS) is an inflammatory and demyelinating disorder of central nervous system that can be diagnosed in pediatric age (<18 years) in 3-5% of the cases. This early onset is associated with higher relapse rates and earlier progression to neurological disability. By using NEDA-3 (No Evidence of Disease Activity-3) criteria, we aimed to identify clinical predictors associated with absence of disease activity and control of disease progression 12 months after the diagnosis, in a cohort of pediatric-onset MS (POMS) patients regularly followed-up in our center...
2023: Frontiers in Neuroscience
https://read.qxmd.com/read/37769430/prevalence-of-2-year-no-evidence-of-disease-activity-neda-3-and-neda-4-in-relapsing-remitting-multiple-sclerosis-a-real-world-study
#19
JOURNAL ARTICLE
V Bazzurri, A Fiore, E Curti, E Tsantes, A Franceschini, F Granella
BACKGROUND: No evidence of disease activity (NEDA) is becoming a gold standard in the evaluation of disease modifying therapies (DMT) in relapsing-remitting multiple sclerosis (RRMS). NEDA-3 status is the absence of relapses, new activity on brain MRI, and disability progression. NEDA-4 meets all NEDA-3 criteria plus lack of brain atrophy. OBJECTIVE: Aim of this study was to investigate the prevalence of two-year NEDA-3, NEDA-4, six-month delayed NEDA-3 (6mdNEDA-3), and six-month delayed NEDA-4 (6mdNEDA-4) in a cohort of patients with RRMS...
November 2023: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/37748927/haematopoietic-stem-cell-transplantation-for-treatment-of-relapsing-remitting-multiple-sclerosis-in-sweden-an-observational-cohort-study
#20
JOURNAL ARTICLE
Thomas Silfverberg, Christina Zjukovskaja, Per Ljungman, Adjmal Nahimi, Erik Ahlstrand, Arta Dreimane, Sigrun Einarsdottir, Jan Fagius, Ellen Iacobaeus, Hans Hägglund, Niclas Lange, Stig Lenhoff, Jan Lycke, Johan Mellergård, Fredrik Piehl, Anders Svenningsson, Andreas Tolf, Honar Cherif, Kristina Carlson, Joachim Burman
BACKGROUND: A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS), but it has not yet been integrated into most national clinical guidelines. The objective of this study was to assess efficacy and safety when aHSCT is implemented in routine healthcare. METHODS: We assessed 231 patients and the final analysis included 174 RRMS patients who were treated with aHSCT in Sweden before 1 January 2020...
September 25, 2023: Journal of Neurology, Neurosurgery, and Psychiatry
keyword
keyword
158176
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.